In September 2023, the Federal Trade Commission sued U.S. Anesthesia Partners and its private equity sponsor, Welsh, Carson, Anderson & Stowe, alleging a decade-long scheme to consolidate anesthesia services in Texas. It was the first major federal case built entirely on a rollup strategy — and every clinic acquirer has read it since.
The complaint's allegations were specific. USAP, created by Welsh Carson in 2012, had bought up nearly every large anesthesia practice in Texas, reaching alleged market shares of about 44% to 70% in Houston, Dallas, and Austin. Beyond acquisitions, the FTC alleged price-setting arrangements with remaining independent groups, billing their services at USAP's higher negotiated rates, and a market-allocation deal paying rival Envision Healthcare $9 million per year for five years to stay out of the Dallas–Fort Worth market. The dominance, the FTC said, cost Texans tens of millions of dollars more each year for anesthesia services than before USAP was created. USAP denied wrongdoing throughout.
The procedural path matters as much as the allegations, because it shows how these cases actually resolve. In May 2024, a federal judge dismissed Welsh Carson from the federal case, finding the Commission lacked authority to proceed against the firm there because the complaint did not accuse it of currently violating the law. The FTC resolved its concerns with Welsh Carson through a separate administrative proceeding in early 2025, requiring the firm to limit its involvement with USAP and to notify regulators of future acquisitions in anesthesia and other hospital-based physician practices. The case against USAP itself continued until April 23, 2026, when the FTC announced an agreement in principle to settle; a federal court stayed the case on May 26, 2026, while USAP implements the required relief over 180 days. The settlement terms are confidential, USAP was not required to admit wrongdoing, and the FTC has said it will return to court if USAP does not follow through. A related private class action continues separately.
Why the case reaches beyond anesthesia is the template it established: stealth consolidation. Serial acquisitions, each individually too small to trigger premerger notification thresholds, can cumulatively produce a dominant market position — and regulators now treat that cumulative position as the violation, not any single deal. The same structure reshaped gastroenterology, dermatology, ophthalmology, and orthopedics using similar approaches, and the same analysis now applies to them. Regulators map market share by metropolitan area and by payer contract, not just by deal size.
What changes in diligence follows directly. Acquirers now model post-deal share by metro area and by payer before signing, rather than discovering it in a second request. They document integration efficiencies — the argument that consolidation lowers cost through shared systems, not merely raises price through market power — because that argument is now the defense that matters. They track state transaction-notice laws and corporate-practice-of-medicine enforcement, which have tightened alongside federal scrutiny. Deals in unconcentrated markets proceed much as before. Deals that would create a dominant local position get restructured, reduced in scope, or abandoned.
Scale itself was never the violation. Local dominance plus price conduct was. The rollup playbook survives the USAP case intact for any acquirer that can show its clinics compete, its integration is real, and its market share in each city it enters leaves payers and patients with genuine alternatives. The version of the playbook that buys every competitor in one city does not survive — and that distinction is now the first question in every rollup investment committee memo.
Sources: Federal Trade Commission, agreement in principle with U.S. Anesthesia Partners (April 23, 2026) and related litigation history, as reported by Becker's ASC, https://www.beckersasc.com/anesthesia/what-the-usap-ftc-settlement-means-for-asc-anesthesia-contracting/. Becker's Physician Leadership, physician acquisition controversies in 2026 (USAP alleged market shares about 44% to 70% in Houston, Dallas, and Austin; decade-long rollup of more than a dozen practices; court stay May 26, 2026; 180-day implementation), https://www.beckersphysicianleadership.com/asc-transactions-and-valuation-issues/5-physician-acquisition-controversies-in-2026/. Market-allocation allegation (Envision Healthcare, $9 million per year for five years, Dallas–Fort Worth) and Welsh Carson procedural history (May 2024 dismissal from the federal case; early 2025 administrative settlement), as reported in Becker's ASC coverage of the case.